# A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

> **NCT04943068** · PHASE3 · COMPLETED · sponsor: **Kwang Dong Pharmaceutical co., ltd.** · enrollment: 193 (actual)

## Conditions studied

- Hypoactive Sexual Desire Disorder

## Interventions

- **DRUG:** Bremelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04943068
- **Lead sponsor:** Kwang Dong Pharmaceutical co., ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-10
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943068, "A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04943068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*